Tactiva Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $35M

  • Investors
  • 7

Tactiva Therapeutics General Information

Description

Operator of an immuno-oncology company intended to specialize in potent cancer immunotherapy using a dual T cell receptor approach. The company's platform consists of engineered cells that generate a durable supply of cells with direct anti-tumor activity as well as a sustained helper function to cell-derived transduced effector T cells, enabling doctors and medical professionals to diagnose and treat life-threatening diseases effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 701 Ellicott Street, 4th Floor
  • Buffalo, NY 14203
  • United States
+1 (716)
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 701 Ellicott Street, 4th Floor
  • Buffalo, NY 14203
  • United States
+1 (716)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tactiva Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 01-Nov-2018 $35M Completed Pre-Clinical Trials
3. Grant Completed Pre-Clinical Trials
2. Accelerator/Incubator 27-Feb-2017 $1.1M $2.6M Completed Pre-Clinical Trials
1. Seed Round 01-Jul-2016 $1.5M $1.5M Completed Startup
To view Tactiva Therapeutics’s complete valuation and funding history, request access »

Tactiva Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1
Series A
To view Tactiva Therapeutics’s complete cap table history, request access »

Tactiva Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tactiva Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Panacea Capital (California) Venture Capital Minority
Shenzhen Yifeng Investment Management Enterprise Venture Capital Minority
VI Ventures Venture Capital Minority
Start-up NY Accelerator/Incubator Minority
Angel (individual)
You’re viewing 5 of 7 investors. Get the full list »

Tactiva Therapeutics FAQs

  • When was Tactiva Therapeutics founded?

    Tactiva Therapeutics was founded in 2016.

  • Where is Tactiva Therapeutics headquartered?

    Tactiva Therapeutics is headquartered in Buffalo, NY.

  • What is the size of Tactiva Therapeutics?

    Tactiva Therapeutics has 4 total employees.

  • What industry is Tactiva Therapeutics in?

    Tactiva Therapeutics’s primary industry is Drug Discovery.

  • Is Tactiva Therapeutics a private or public company?

    Tactiva Therapeutics is a Private company.

  • What is the current valuation of Tactiva Therapeutics?

    The current valuation of Tactiva Therapeutics is .

  • What is Tactiva Therapeutics’s current revenue?

    The current revenue for Tactiva Therapeutics is .

  • How much funding has Tactiva Therapeutics raised over time?

    Tactiva Therapeutics has raised $37.6M.

  • Who are Tactiva Therapeutics’s investors?

    Panacea Capital (California), Shenzhen Yifeng Investment Management Enterprise, VI Ventures, Start-up NY, and are 5 of 7 investors who have invested in Tactiva Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process